[Respiratory deterioration and allergic bronchopulmonary aspergillosis in cystic fibrosis].
Salcedo Posadas
A
A
Unidad de Fibrosis Quística, Hospital Infantil Universitario Niño Jesús, Madrid.
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications*; D018450:Disease Progression; D004198:Disease Susceptibility; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000175:diagnosis / Q000209:etiology*; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000209:etiology; D007223:Infant; D017964:Itraconazole / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012129:Respiratory Function Tests; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D017964:Itraconazole; D011241:Prednisone